The thyroid gland — a small butterfly-shaped structure at the base of the neck — produces hormones that regulate virtually every metabolic process in the body. Heart rate, body temperature, energy production, cholesterol metabolism, and the function of almost every organ system are influenced by thyroid hormone levels. What is less commonly known — including among couples undergoing fertility treatment — is the profound influence thyroid function has on reproductive health.
Thyroid dysfunction is the second most common endocrine disorder in women of reproductive age in India, after PCOS. Hypothyroidism — underactive thyroid — affects an estimated 10 to 12 percent of Indian women. Autoimmune thyroid disease — in which the immune system produces antibodies against the thyroid gland — is even more prevalent. And both of these conditions can significantly impair fertility and increase pregnancy loss risk — even when the thyroid dysfunction is mild enough to produce no obvious symptoms and to fall within what most laboratories define as the normal TSH range.
The connection between thyroid function and fertility is one of the most commonly overlooked dimensions of the infertility work-up. At many clinics, thyroid assessment means a single TSH measurement — which, if it falls within the broad laboratory reference range, is recorded as normal and dismissed from the clinical picture. What this misses — the fertility-specific TSH target, the significance of thyroid antibodies in euthyroid women, and the specific mechanisms through which thyroid dysfunction impairs ovulation, implantation, and early pregnancy maintenance — is the subject of this article.
How the Thyroid Affects Fertility — the Biological Mechanisms
Understanding why thyroid function matters for fertility requires understanding the specific pathways through which thyroid hormones interact with the reproductive system.
Thyroid hormones and ovulation. Thyroid hormones directly influence the hypothalamic-pituitary-ovarian axis — the hormonal signaling chain that drives follicle development and ovulation. Hypothyroidism disrupts this axis by increasing thyrotropin-releasing hormone (TRH) from the hypothalamus, which in turn stimulates not only TSH release (the standard clinical measurement) but also prolactin release from the pituitary. Elevated prolactin — hyperprolactinemia — suppresses GnRH and LH pulsatility, impairing follicle development and ovulation. Women with hypothyroidism may have irregular cycles, anovulation, or luteal phase defects — all of which reduce the frequency of fertile cycles.
Thyroid hormones and implantation. The endometrium — the uterine lining where implantation must occur — expresses thyroid hormone receptors. Thyroid hormones influence endometrial development and the expression of the molecular signals — including integrins, pinopodes, and LIF (leukaemia inhibitory factor) — that mediate embryo implantation. Suboptimal thyroid hormone levels may impair the endometrial receptivity that successful implantation requires.
Thyroid hormones and early pregnancy maintenance. In the first trimester of pregnancy, the embryo and developing placenta depend entirely on maternal thyroid hormone — the fetal thyroid does not begin functioning until approximately 12 weeks of gestation. Adequate maternal thyroid hormone is essential for normal fetal neurological development in the first trimester. Hypothyroidism in early pregnancy — even mild hypothyroidism that produced no symptoms before pregnancy — increases the risk of miscarriage, premature birth, and fetal neurological impairment.
The TSH shift in early pregnancy. Normal TSH levels change in early pregnancy — hCG (the pregnancy hormone) cross-reacts with the TSH receptor and has a mild thyroid-stimulating effect, suppressing TSH in the first trimester. A woman with borderline hypothyroidism before pregnancy — TSH between 2.5 and 4.0 mIU/L — may have adequate thyroid hormone for her non-pregnant state but inadequate thyroid hormone reserve to meet the increased demands of early pregnancy when the TSH suppression from hCG reduces her pituitary's compensatory drive. This is one reason why the fertility-specific TSH target is lower than the general laboratory normal range.
The TSH Target for Fertility — Why 2.5 mIU/L Matters
The general laboratory reference range for TSH in most Indian laboratories is approximately 0.4 to 4.5 or 5.0 mIU/L. A TSH of 3.8 mIU/L is within this range. A TSH of 4.2 mIU/L is within this range. These results are reported as normal — and in most clinical contexts, they are.
In the fertility context, the reference range is not the appropriate target.
Current evidence — from multiple large studies examining the relationship between TSH levels and IVF outcomes — consistently supports a lower TSH target for women undergoing fertility treatment. The Endocrine Society guidelines for pregnancy and thyroid disease recommend that women who are pregnant — or planning to become pregnant — maintain a TSH below 2.5 mIU/L in the first trimester. For women undergoing IVF, pre-cycle TSH optimization to below 2.5 mIU/L is widely recommended — because the early pregnancy that follows a successful IVF transfer immediately places the same physiological demands on thyroid function as any other first-trimester pregnancy, and the maternal thyroid reserve must be adequate to meet those demands from the earliest days.
The practical implication is clear and specific. A woman with a TSH of 3.8 mIU/L undergoing IVF has a TSH that is normal by laboratory standards and suboptimal by fertility standards. If her TSH is not optimized to below 2.5 mIU/L before transfer, the early pregnancy — if it establishes — begins from a position of borderline thyroid insufficiency. Levothyroxine — in a small dose, titrated to bring the TSH to the target — addresses this gap inexpensively, safely, and reliably.
At Metro IVF, TSH optimization to below 2.5 mIU/L before IVF transfer is a standard component of the pre-cycle protocol for every woman whose TSH falls above this threshold — regardless of whether the TSH falls within the general laboratory normal range. This is not an exotic intervention. It is a simple, evidence-based optimization that takes a potential limitation of the early pregnancy environment and removes it.
Thyroid Antibodies — The Hidden Dimension of Thyroid Assessment
The second and more commonly overlooked dimension of thyroid assessment in fertility is the measurement of thyroid antibodies — specifically anti-thyroid peroxidase (anti-TPO) antibodies and, in some clinical contexts, anti-thyroglobulin antibodies.
Thyroid antibodies are produced by the immune system against components of the thyroid gland. Their presence indicates autoimmune thyroid disease — the body's immune system targeting the thyroid tissue — most commonly Hashimoto's thyroiditis. In established Hashimoto's thyroiditis, autoimmune destruction of thyroid tissue progressively reduces thyroid function, eventually producing clinical hypothyroidism.
But the fertility implications of thyroid antibodies extend beyond the thyroid function they predict. In euthyroid women — women with normal TSH and normal thyroid hormone levels — the presence of thyroid antibodies is independently associated with impaired fertility and increased miscarriage risk, even when thyroid function is currently normal.
The mechanisms through which thyroid antibodies impair fertility in euthyroid women are not fully understood. Proposed mechanisms include direct effects of thyroid antibodies on the endometrial immune environment — altering the balance of immune cells and cytokines at the implantation site — and the association between thyroid autoimmunity and other autoimmune processes that may independently impair implantation or early pregnancy maintenance. Women with thyroid antibodies also have a higher risk of developing overt hypothyroidism during pregnancy — even from a currently euthyroid state — and require closer monitoring.
The clinical significance is substantial and is reflected in the data. Multiple meta-analyses have demonstrated that euthyroid women with positive anti-TPO antibodies undergoing IVF have higher miscarriage rates and lower live birth rates than euthyroid women without antibodies, even when TSH is well within the normal range in both groups. The antibodies themselves — not only the thyroid function they predict — appear to be clinically meaningful.
This finding has direct implications for the fertility investigation. A TSH that is within the normal range does not exclude thyroid-related fertility impairment if thyroid antibodies are present. A complete thyroid assessment for fertility purposes includes both TSH and anti-TPO antibodies — and a normal TSH in the presence of elevated anti-TPO antibodies is not a complete reassurance.
Subclinical Hypothyroidism — the Clinical Grey Zone
Subclinical hypothyroidism is defined as a TSH above the upper limit of the reference range with normal thyroid hormone levels (normal free T4 and free T3). It is the mildest form of thyroid dysfunction — producing no clinical symptoms in most patients, identified only on blood testing — but it carries specific fertility implications that make its identification and management clinically important.
In women with subclinical hypothyroidism and infertility or recurrent miscarriage, the evidence supports treatment with levothyroxine to normalize TSH. The 2021 ATA (American Thyroid Association) guidelines recommend levothyroxine treatment in women with subclinical hypothyroidism who are planning pregnancy or undergoing IVF — the treatment is safe, inexpensive, and addresses a modifiable factor that is associated with impaired outcomes if untreated.
The optimal TSH target during fertility treatment in subclinical hypothyroidism is below 2.5 mIU/L — the same target as for euthyroid women undergoing IVF, reflecting the same physiological rationale.
Hyperthyroidism and Fertility
While hypothyroidism is the more commonly encountered thyroid dysfunction in the fertility context, hyperthyroidism — overactive thyroid — also has fertility implications that deserve brief mention.
Hyperthyroidism — most commonly due to Graves' disease — causes menstrual irregularity, reduced fertility, and elevated miscarriage risk through mechanisms including direct disruption of the hypothalamic-pituitary axis, increased sex hormone binding globulin (which reduces free estrogen and progesterone), and the metabolic stress of the hyperthyroid state.
Women with known or suspected hyperthyroidism should be evaluated and treated before attempting fertility treatment — including IVF. The elevated hCG of early pregnancy can worsen hyperthyroidism in Graves' disease, and uncontrolled hyperthyroidism in pregnancy carries significant fetal risks.
Thyroid Assessment in the Male Partner
Thyroid function is relevant not only to the female partner. Thyroid hormones influence spermatogenesis — hypothyroidism in men is associated with reduced sperm parameters including reduced motility and increased morphological abnormalities. Hyperthyroidism in men is associated with elevated sperm DNA fragmentation and reduced sperm quality.
While thyroid dysfunction is less common in men than in women, thyroid assessment in the male partner — particularly when sperm parameters are abnormal or when sperm DNA fragmentation is elevated — is part of the comprehensive evaluation at Metro IVF.
The India-Specific Context — Iodine Deficiency and Thyroid Disease
India has historically had pockets of significant iodine deficiency — particularly in inland areas, hilly regions, and the tribal belts of Central India — that have contributed to endemic thyroid disease including hypothyroidism and goitre. Despite the widespread introduction of iodized salt, iodine deficiency remains a concern in specific geographic areas.
In the tribal belt of Chhattisgarh — the geographic region that Metro IVF serves — thyroid disease related to both autoimmune causes and historical iodine deficiency is prevalent, and the fertility implications of underdiagnosed and undertreated thyroid dysfunction in this population are significant.
Routine thyroid assessment — TSH and anti-TPO antibodies — in every couple presenting for fertility evaluation at Metro IVF is particularly important in this context. Identifying and treating thyroid dysfunction in couples from this region is not simply a clinical intervention for an individual — it is a contribution to the reproductive health of a population where the condition is prevalent and awareness is lower than in urban centers.
How Metro IVF Manages Thyroid Assessment
At Metro IVF in Ambikapur, the thyroid assessment for every woman presenting for fertility evaluation includes both TSH and anti-TPO antibodies — as a routine, non-optional component of the work-up.
TSH results are evaluated against the fertility-specific target of below 2.5 mIU/L rather than against the general laboratory reference range. Women whose TSH falls between 2.5 and the upper limit of the laboratory reference range are offered levothyroxine — with a discussion of the evidence for TSH optimization in fertility treatment and the simple, safe, effective nature of the intervention.
Women with positive anti-TPO antibodies — regardless of their current TSH — are monitored closely. TSH is checked at the time of a positive pregnancy test and at regular intervals in early pregnancy, because the pregnancy-related changes in thyroid demand can unmask thyroid insufficiency in antibody-positive women whose pre-pregnancy TSH was adequate. Levothyroxine is initiated promptly if TSH rises above 2.5 mIU/L in early pregnancy.
For women with established hypothyroidism already on levothyroxine, the dose is reviewed in the context of the fertility-specific TSH target. Women whose TSH is controlled to 3.0 mIU/L on their current dose — well within the general treatment target — may need a dose adjustment to achieve the stricter fertility target before an IVF cycle.
The Message This Article Is Written to Deliver
There is a specific clinical message that this article is designed to communicate to every woman — and every couple — who reads it.
If your thyroid has been assessed only by a TSH measurement — without anti-TPO antibody testing — your thyroid assessment is incomplete for fertility purposes.
If your TSH is within the general laboratory normal range but above 2.5 mIU/L — your TSH is not optimized for fertility.
If you have been told your thyroid is normal because your TSH is normal — ask whether your anti-TPO antibodies have been tested.
These are not esoteric clinical questions. They are simple, specific, actionable questions about a routine, inexpensive, easily obtainable set of tests that can reveal a modifiable contributor to infertility that — when identified and addressed — improves fertility outcomes in a well-documented and clinically meaningful way.
At Metro IVF, these questions are not questions that need to be asked — because the answers are obtained routinely, as part of every fertility assessment, before the clinical picture is considered complete.
Your Next Step
If you are undergoing fertility treatment and your thyroid has been assessed only by TSH without antibody testing — or if your TSH has been recorded as normal without reference to the fertility-specific target of below 2.5 mIU/L — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur will provide the complete thyroid assessment that your fertility evaluation requires.
The thyroid-infertility connection is real, specific, and addressable. It deserves to be looked for — and addressed — in every couple undergoing fertility treatment.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Your thyroid may be affecting your fertility in ways your previous assessment did not reveal. Book your consultation with Dr. Ashish Soni at Metro IVF today.